Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Philip J. Mease(Providence College), J. Wollenhaupt(Schön Klinik Hamburg Eilbek), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Dafna D. Gladman(Toronto Western Hospital), Juan J. Gómez‐Reino(Hospital Clínico Universitario de Valencia), Éric Lespessailles(Université d'Orléans), Arthur Kavanaugh(University of California System), Maria Paris(Amgen (United States)), Lichen Teng(Harbin Medical University), Georg Schett(Karolinska University Hospital), Stephen Hall(Cabrini Hospital)
Cited by 21
Related Papers
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913